New hope for kidney patients: avacopan combo trial launches
NCT ID NCT06676579
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This study tests whether the drug avacopan, combined with a low-dose steroid, can help people with a severe form of IgA nephropathy (a kidney disease). The goal is to reduce protein in the urine and protect kidney function. About 16 adults with active disease and high risk of worsening will take part. The trial is open-label and randomized, meaning everyone knows what treatment they receive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224, United States
Contact
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Conditions
Explore the condition pages connected to this study.